ClinicalTrials.gg
CompletedNCT02606877Updated Mar 4, 2019Results posted

A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination

A Phase 4 interventional study of nintedanib and pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 9 sites in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-03-04.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
10th of 16
37 · median 49
Started
2016
with 2 others
Phase 4
5 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
6 of 16
Boehringer Ingelheim

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 10th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 4, and was the 6th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the effect of steady state pirfenidone on the pharmacokinetics of nintedanib and its metabolites following oral administration of 2403 mg/day pirfenidone and to investigate the effect of steady state nintedanib on the pharmacokinetics of pirfenidone at steady state following oral administration of 150 mg bid nintedanib. There will be two cohorts of patients; the first one will consist of patients not treated with pirfenidone or nintedanib, while the second one will consist of patients on pirfenidone treatment.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Any patients diagnosed with IPF and who comply with eligibility requirements may qualify for participation in the trial.

  • Written consistent with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local laws, signed prior to any study procedures being performed (including any required ).
  • Male or female patients aged >=40 years at Visit 1
  • IPF diagnosis, based upon the American Thoracic Society (ATS)/European Respiratory Society(ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) 2011 guideline and chest high-resolution computed tomography (HRCT) scan.
  • Force Vital Capacity (FVC) >=50% of predicted normal at Visit 1
  • Diffusing capacity of the Lung for Carbon monoxide (DLCO) (corrected for [visit 1]): 30%-79% predicted of normal at visit 2. (test can be performed at visits 1 or 2, or during the screening period)
  • Currently treated with pirfenidone at full dose (this is only for patients going into Group 2).

Exclusion criteria

Exclusion criteria:

  • (ALT), Aspartate aminotransferase (AST) >1.5 fold (ULN) at visit 1.
  • Total >1.5 fold ULN at visit 1.
  • Underlying chronic liver disease ( A, B, or C hepatic impairment)
  • Relevant airways obstruction (i.e. pre-bronchodilator (FEV1)/FVC \<0.7 at visit 1).
  • History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1.
  • Bleeding Risk:
  • Known genetic predisposition to bleeding
  • Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin, etc.) or high dose antiplatelet therapy.
  • History of haemorrhagic central nervous system (CNS) event within 12 months prior to visit 1.
  • History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1.
  • (INR) >2 at visit 1.
  • Prothrombin time (PT) and partial thromboplastin time (PTT) >150% of institutional ULN at visit 1.
  • Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery.
  • History of thrombotic event (including stroke and ) within 12 months of visit 1.
  • Severe renal impairment ( \<30 mL/min calculated by Cockcroft-Gault formula at visit 1) or end-stage renal disease requiring dialysis.
  • Treatment with n-acetylcysteine, prednisone >15 mg daily or >30 mg every 2 days OR equivalent dose of other oral or fluvoxamine within 2 weeks of visit 2.
  • Treatment with azathioprine, cyclophosphamide, cyclosporine as well as any other drug within 8 weeks of visit 2.
  • Previous treatment with pirfenidone in the past three months prior to Visit 2 (Group 1 only).
  • Previous treatment with nintedanib in the past 14 days prior to Visit 2.
  • Permanent discontinuation of nintedanib or pirfenidone in the past due to adverse events considered drug-related.
  • Known to nintedanib, pirfenidone or their ; or to peanut or soya.
  • A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial.
  • Alcohol or drug abuse, which in the opinion of the treating physician would interfere with treatment.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Women of not using highly effective methods of per ICH M3, note 3, highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner. Barrier contraceptives (e.g. male condom or diaphragm) are acceptable if used in combination with spermicides (e.g. foam, gel). Contraception must be used for 28 days prior to and 3 months after nintedanib and pirfenidone administration.
  • Patients not able to understand and follow study procedures including completion of diaries without help.
  • Current smoker (vaping and e-cigarettes are acceptable)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Treatment naïve

    Treatment naïve to pirfenidone

    Drug: nintedanib · Drug: pirfenidone

  • Experimental
    Pirfenidone-treated

    Treatment before with pirfenidone

    Drug: nintedanib · Drug: pirfenidone

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).

    AUC0-tz , area under the concentration-time curve of nintedanib in plasma over the time interval from 0 to the last quantifiable concentration. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

    Time frame: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

  2. Treatment naïve, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration (Cmax).

    Cmax, maximum measured concentration of nintedanib in plasma. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

    Time frame: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

  3. Pirfenidone-treated, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over a Dosing Interval at Steady State (AUCτ,ss)

    AUCτ,ss, area under the concentration-time curve of pirfenidone in plasma over a dosing interval at steady state. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

    Time frame: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

  4. Pirfenidone-treated, Maximum Measured Concentration of Pirfenidone in Plasma at Steady State (Cmax,ss)

    Cmax,ss, maximum measured concentration of pirfenidone in plasma at steady state. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

    Time frame: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

Secondary outcomes

  1. Treatment naïve, Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞, area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

    Time frame: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

07

Results

Posted Mar 4, 2019

Participant flow

This was an open-label, multiple-dose, 2-group trial in patients with idiopathic pulmonary fibrosis (IPF) to investigate the relative bioavailability of nintedanib and pirfenidone when administered alone and after coadministration.

Participant flow — Overall Study
MilestoneTreatment naïvePirfenidone-treated
Started2017
Completed1616
Not completed41
Withdrew: Adverse event30
Withdrew: Non-compliance with protocol01
Withdrew: Other than listed above10

Outcome measures

PrimaryTreatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).

AUC0-tz , area under the concentration-time curve of nintedanib in plasma over the time interval from 0 to the last quantifiable concentration. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

Time frame:
Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.
Reported as:
Geometric mean · nanogram*hour/mililitre [ng*h/mL]
Treatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).
nanogram*hour/mililitre [ng*h/mL]Nintedanib + Pirfenidone (T1)Nintedanib (R1)
Treatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).150.31 ± 1.18169.69 ± 1.15
Statistical analysis
  • Nintedanib + Pirfenidone (T1) vs Nintedanib (R1) · ANOVA · T1/r1 ratio (%): 88.58 · 90% CI 65.40 to 119.97To get,geometric mean ratio and Confidence Interval,least square estimates of log-transformed PK endpoint for T1 and R1 were back transformed to original scale. Standard Deviation is actually the intra-individual geometric Coefficient of Variance(%).
PrimaryTreatment naïve, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration (Cmax).

Cmax, maximum measured concentration of nintedanib in plasma. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

Time frame:
Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.
Reported as:
Geometric mean · nanogram/mililitre [ng/mL]
Treatment naïve, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration (Cmax).
nanogram/mililitre [ng/mL]Nintedanib + Pirfenidone (T1)Nintedanib (R1)
Treatment naïve, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration (Cmax).23.04 ± 1.2328.58 ± 1.19
Statistical analysis
  • Nintedanib + Pirfenidone (T1) vs Nintedanib (R1) · ANOVA · T1/r1 ratio (%): 80.63 · 90% CI 51.27 to 126.79To get,geometric mean ratio and Confidence Interval,least square estimates of log-transformed PK endpoint for T1 and R1 were back transformed to original scale. Standard Deviation is actually the intra-individual geometric Coefficient of Variance(%).
PrimaryPirfenidone-treated, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over a Dosing Interval at Steady State (AUCτ,ss)

AUCτ,ss, area under the concentration-time curve of pirfenidone in plasma over a dosing interval at steady state. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

Time frame:
Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.
Reported as:
Geometric mean · nanogram*hour/mililitre [ng*h/mL]
Pirfenidone-treated, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over a Dosing Interval at Steady State (AUCτ,ss)
nanogram*hour/mililitre [ng*h/mL]Pirfenidone+Nintedanib (T2)Pirfenidone (R2)
Pirfenidone-treated, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over a Dosing Interval at Steady State (AUCτ,ss)39040.84 ± 1.0740178.46 ± 1.07
Statistical analysis
  • Pirfenidone+Nintedanib (T2) vs Pirfenidone (R2) · ANOVA · T2/r2 ratio (%): 97.17 · 90% CI 87.84 to 107.48To get,geometric mean ratio and Confidence Interval,least square estimates of log-transformed PK endpoint for T2 and R2 were back transformed to original scale. Standard Deviation is actually the intra-individual geometric Coefficient of Variance(%).
PrimaryPirfenidone-treated, Maximum Measured Concentration of Pirfenidone in Plasma at Steady State (Cmax,ss)

Cmax,ss, maximum measured concentration of pirfenidone in plasma at steady state. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

Time frame:
Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.
Reported as:
Geometric mean · nanogram/mililitre [ng/mL]
Pirfenidone-treated, Maximum Measured Concentration of Pirfenidone in Plasma at Steady State (Cmax,ss)
nanogram/mililitre [ng/mL]Pirfenidone+Nintedanib (T2)Pirfenidone (R2)
Pirfenidone-treated, Maximum Measured Concentration of Pirfenidone in Plasma at Steady State (Cmax,ss)10537.26 ± 1.0810591.08 ± 1.08
Statistical analysis
  • Pirfenidone+Nintedanib (T2) vs Pirfenidone (R2) · ANOVA · T2/r2 ratio (%): 99.49 · 90% CI 87.94 to 112.56To get,geometric mean ratio and Confidence Interval,least square estimates of log-transformed PK endpoint for T2 and R2 were back transformed to original scale. Standard Deviation is actually the intra-individual geometric Coefficient of Variance(%).
SecondaryTreatment naïve, Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞, area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error.

Time frame:
Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.
Reported as:
Geometric mean · nanogram*hour/mililitre [ng*h/mL]
Treatment naïve, Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
nanogram*hour/mililitre [ng*h/mL]Nintedanib + Pirfenidone (T1)Nintedanib (R1)
Treatment naïve, Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)175.04 ± 1.18195.59 ± 1.15
Statistical analysis
  • Nintedanib + Pirfenidone (T1) vs Nintedanib (R1) · ANOVA · T1/r1 ratio (%): 89.49 · 90% CI 66.33 to 120.73To get,geometric mean ratio and Confidence Interval,least square estimates of log-transformed PK endpoint for T1 and R1 were back transformed to original scale. Standard Deviation is actually the intra-individual geometric Coefficient of Variance(%).

Adverse events

Collected over From first drug administration until 28 days after last drug administration, up to 6 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment naïve0/20 (0%)0/20 (0%)13/20 (65%)
Pirfenidone-treated0/17 (0%)0/17 (0%)15/17 (88.2%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTreatment naïvePirfenidone-treated
Lower respiratory tract infectionInfections and infestations1/206/17
DiarrhoeaGastrointestinal disorders6/204/17
NauseaGastrointestinal disorders5/203/17
HeadacheNervous system disorders5/200/17
CoughRespiratory, thoracic and mediastinal disorders2/204/17
DyspepsiaGastrointestinal disorders4/200/17
FatigueGeneral disorders4/200/17
VomitingGastrointestinal disorders3/202/17
Upper respiratory tract infectionInfections and infestations1/202/17
DyspnoeaRespiratory, thoracic and mediastinal disorders1/202/17

Baseline characteristics

Treated set (TS): The TS includes all patients who received at least 1 dose of trial medication

Age, Continuous
Age, Continuous(Years)Treatment naïvePirfenidone-treatedTotal
Mean71.5 ± 7.868.3 ± 7.470.0 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Treatment naïvePirfenidone-treatedTotal
Female9211
Male111526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment naïvePirfenidone-treatedTotal
Hispanic or Latino112
Not Hispanic or Latino191635
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment naïvePirfenidone-treatedTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American000
White181634
More than one race000
Unknown or Not Reported000
08

Study locations

9 sites
  • Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
  • Papworth Hospital
    Cambridge, CB23 3RE, United Kingdom
  • Glenfield Hospital
    Leicester, LE3 9QP, United Kingdom
  • University College London Hospital
    London, NW1 2PG, United Kingdom
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Mar 2017, 11 months.

Results were first posted in Mar 2019, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Nov 17, 2015
StartActual
Apr 19, 2016
Primary completionActual
Mar 22, 2017
CompletionActual
Mar 22, 2017
Results first posted
Mar 4, 2019
Last update
Mar 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02606877
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Apr 19, 2016
Primary completion
Mar 22, 2017
Completion
Mar 22, 2017
Results posted
Mar 4, 2019
Last update
Mar 4, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Pirfenidone

Start the discussion